Alec Broers becomes chairman of Bio Nano Consulting

Brings extensive industry, academic and scientific expertise to company

Bio Nano Consulting, a UK specialist in bio and nanotechnology partnerships between the academic and industrial sectors, has appointed Professor Lord Alec Broers as chairman of the board.

Broers has extensive industry, academic and scientific expertise and was chairman of the House of Lords Science and Technology Select Committee between 2004 and 2007.

At Bio Nano Consulting he will facilitate ongoing partnerships between academia and the wider life science and technology industries.

Educated at Melbourne University and the University of Cambridge, Broers subsequently worked in r&d at IBM laboratories in the US for 19 years, ultimately taking responsibility for the company’s chip development.

Broers returned to the UK in 1984 as head of Electrical Engineering at Cambridge University and Fellow of Trinity College. He subsequently became head of the Department of Engineering and Master of Churchill College.

More recently, Broers was Vice Chancellor of Cambridge University and president of the Royal Academy of Engineering from 2001 to 2006. He was knighted in 1998 for services to education before being made a life peer in 2004.

Bio Nano Consulting is a joint venture of Imperial College London and University College London that specialises in solutions to industry across the life sciences and technology sectors.

You may also like

Research & Development

NanoKTN facilitates cancer drug partnership

BNC and London University School of Pharmacy sign service level agreement
Manufacturing

Bio Nano Consulting clinches cancer drug formulation contract

Signs agreement with University of London School of Pharmacy
Research & Development

Quotient Sciences and CPI to accelerate RNA drug development with joint venture

The JV will address the growing industry demand for agile solutions that bring new RNA therapeutics to patients with greater speed and confidence
Research & Development

Naobios, Nuvonis and the European Vaccine Initiative collaborate to manufacture influenza challenge agent

Working with the Inno4Vac consortium, Naobios will leverage Nuvonis’s Vero Cell Bank to support the development of a controlled human infection model based on the influenza virus A(H3N2)
Research & Development

Wegovy cuts risk of heart attack, stroke or death by 57% compared with tirzepatide

Study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy are specific to the semaglutide molecule and therefore cannot be extended to other GLP-1 or GIP/GLP-1-based treatments
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Formulation meets function: addressing palatability in drug development (part I)

Patient adherence to treatment regimens is inextricably linked to the palatability of medications, with consequences that can be far more serious than simply leaving a bad taste in one’s mouth
Research & Development

Hamilton Health Sciences chosen for BirchBioMed burn scar treatment trial

BirchBioMed announces Hamilton Health Sciences’ (HHS) Centre for Burn Research in Ontario as the first contracted clinical trial site for its Phase II/III randomised study of the naturally based compound: FS2.
Subscribe now